ArticleEuropean journal of immunology2026
Adapted Live SARS-CoV-2 Vaccine Elicits Rapid Mucosal Immunity, Protects From Disease, and Reduces Shedding of XBB.1.5.
Article in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The emergence of SARS-CoV-2 variants, like XBB.1.5, causing immune evasion and frequent breakthrough infections, emphasizes the need for vaccines that limit transmission and target newly emerging variants. Mucosal vaccines, particularly live attenuated vaccines (LAV), are promising candidates for inducing strong mucosal immune responses to prevent viral replication and transmission. Vaccination with the previously described "one-to-stop" codon-modified LAV OTS-228, carrying the ancestral spike protein, induced sterilizing immunity against ancestral SARS-CoV-2 but also broad protection against Omicron variants, including XBB.1.5, but transmission of XBB.1.5 to contacts could not be prevented completely. As a proof-of-concept, we updated OTS-228 by replacing the sequence coding for the ancestral SARS-CoV-2 spike protein with that of the XBB.1.5 variant. We applied flow cytometry to detect SARS-CoV-2-specific T cell responses, as well as ELISA and qPCR, to characterize systemic and mucosal immune responses in Syrian hamsters in detail. The new OTS construct designated as "OTS-300" exhibited an optimal safety profile in Syrian hamsters comparable to the original candidate vaccine. A single-dose intranasal (i.n.) vaccination with OTS-300 protects against disease, substantially limits XBB.1.5 replication, and reduces transmission in Syrian hamsters, showcasing the adaptability of the OTS platform for other emerging variants. OTS-300 induced accelerated mucosal and systemic antibody responses and reduced virus-mediated inflammation as compared with an intramuscularly delivered mRNA vaccine encoding the XBB.1.5 Spike.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.